8th International Congress on Cancer Metastasis
L

The Genomic Evolution of Breast Cancer Metastasis: Metastases Mostly Disseminate Late from Primary Breast Tumors, Keeping Most Drivers

By 8th International Congress on Cancer Metastasis FEATURING Lucy Yates
By 8th International Congress on Cancer Metastasis FEATURING Lucy Yates
9 views
January 17, 2020
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
08:48
James Martin

2L Therapy for ER+ mBC Following CDK4/6i

14:54
Grace Choong

Resistance Mutations in HR+ mBC After 1L ET + CDK4/6i: Next Lines an…

08:54
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for Pat…

Feat. S. Tolaney, H. Rugo
26:30
Insights from 2023 SABCS

SABCS 2023 Summary: "HER2+ BC Highlights From KATHERINE & H…

Feat. S. Tolaney, H. Rugo
35:14
OncoAlert

Advanced TNBC Updates

Feat. H. Rugo
23:52
Cleveland Clinic Taussig Cancer Institute

Targetable Mutations in HR+/HER2- mBC

Feat. M. Kruse
09:51
Cleveland Clinic Taussig Cancer Institute

Mitigation of Cytopenia and Diarrhea Associated With Sacituzumab Gov…

Feat. E. Roesch
07:49
ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023 KEYNOTE-355 Trial: Outcomes in TNBC Patients…

Feat. H. Rugo